Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a daily pill stop hereditary angioedema attacks?

NCT ID NCT05047185

NEW Terminated Disease control Sponsor: Pharvaris Netherlands B.V. Source: ClinicalTrials.gov ↗

First seen Aug 17, 2026 · Last updated Aug 17, 2026

Summary

This trial tests whether an experimental oral medication, deucrictibant, can reduce the number of swelling attacks in people with hereditary angioedema (HAE) types I and II. Participants take either a low or high dose of the drug or a placebo for 12 weeks, and then may continue on the drug in an open-label phase. The goal is to see if the drug safely lowers the monthly rate of confirmed HAE attacks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Deucrictibant (PHA-022121), an oral medication taken daily to prevent swelling attacks
What this could lead to
If successful, this could lead to a convenient daily pill that reduces the frequency of painful and potentially dangerous swelling attacks in people with hereditary angioedema.
What could go wrong
This is an early-phase trial with a small number of participants, so results may not hold up in larger studies. The drug may also have side effects or prove no better than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for C1 ESTERASE INHIBITOR DEFICIENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

C1 inhibitor deficiency hereditary angioedema hereditary angioedema type 1 hereditary angioedema type 2 Hereditary Angioedema Types I and II hereditary angioedema with C1Inh deficiency angioedema prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

C1 ESTERASE INHIBITOR DEFICIENCY C1 INHIBITOR DEFICIENCY HEREDITARY ANGIOEDEMA HEREDITARY ANGIOEDEMA - TYPE 1 HEREDITARY ANGIOEDEMA - TYPE 2 HEREDITARY ANGIOEDEMA ATTACK HEREDITARY ANGIOEDEMA TYPE I HEREDITARY ANGIOEDEMA TYPE II HEREDITARY ANGIOEDEMA TYPES I AND II HEREDITARY ANGIOEDEMA WITH C1 ESTERASE INHIBITOR DEFICIENCY

Contacts and locations

Locations

  • Study Site

    Vienna, A-1090, Austria

  • Study site

    Birmingham, Alabama, 35209, United States

  • Study site

    Paradise Valley, Arizona, 85253, United States

  • Study site

    St Louis, Missouri, 63141, United States

  • Study site

    Sofia, 1680, Bulgaria

  • Study site

    Ottawa, Ontario, K1H 1E4, Canada

  • Study site

    Montreal, Quebec, H2W 1R7, Canada

  • Study site

    Berlin, 10117, Germany

  • Study site

    Frankfurt, 60323, Germany

  • Study site

    Dublin, D08NHY1, Ireland

  • Study site

    Padua, PD, 35128, Italy

  • Study site

    Milan, 20157, Italy

  • Study site

    Palermo, 0146, Italy

  • Study site

    Krakow, Poland

  • Study site

    Brighton, England, BN2 1ES, United Kingdom

  • Study site

    Bristol, England, BS10 5NB, United Kingdom

  • Study site

    Cambridge, England, CB2 0QQ, United Kingdom

  • Study site

    London, England, E1 1FR, United Kingdom

  • Study site

    Southampton, England, SO16 6YD, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.